New NCCN guidelines include expanded genetic risk assessment for various cancers

Busi­ness is boom­ing for Unit­ed­Health­care’s trans­par­ent-pric­ing health plan, as more com­pa­nies con­sid­er of­fer­ing al­ter­na­tive types of health in­sur­ance. The plan, called Surest, aims to fix

Pfiz­er is end­ing the de­vel­op­ment and com­mer­cial­iza­tion of its he­mo­phil­ia B gene ther­a­py Be­qvez, the com­pa­ny con­firmed in an emailed state­ment to End­points News. …